Merck Vs. Pfizer: Why Analyst Upgrades One Pharmaceutical Stock, While Downgrading Another
The health care sector held up relatively well in a difficult year for stocks in 2022. On Wednesday, one analyst adjusted his coverage of two large cap pharmaceutical stocks heading into what could be a volatile 2023.